Tomeglovir

Tomeglovir is a potent anti-CMV agent, inhibiting processing of viral DNA-concatemers, with IC₅₀s of 0.34 μM and 0.039 μM for HCMV and MCMV. IC50 & Target: IC50: 0.34 μM (HCMV), 0.039 μM (MCMV)^[1] In Vitro: Tomeglovir (BAY 38-4766) is a potent anti-CMV agent, with IC₅₀s of 0.34 μM and 0.039 μM for HCMV and MCMV. Tomeglovir also suppresses HELF and NIH 3T3 cells, with CC₅₀s of 85 μM and 62.5 μM, respectively^[1]. Tomeglovir (BAY 38-4766) inhibits HCMV Davis and various monkey CMV strains with EC₅₀s of 1.03 ± 0.57 μM and < 1 μM^[2]. In Vivo: Tomeglovir (BAY 38-4766; 3, 10, 30, 100 mg/kg, p.o.) dose-dependently reduces MCMV-DNA in salivary glands, livers and kidneys of MCMV-infected NOD-SCID mice, and prolongs the survival of the mice. Tomeglovir (10, 25 and 50 mg/kg) shows antiviral activity in the hollow fiber mouse model^[1]. Tomeglovir (BAY 38-4766) shows antiviral activity in SCID mice with MCMV, and the LD₅₀ is >2000 mg/kg in mice and rats^[2].